OncLive TV

Dr Muffly on the Role of Obe-Cel in R/R B-Cell Precursor ALL

February 5th 2025

Dr Phull on Real-World vs Trial Data for CAR T-Cell Therapy in R/R Multiple Myeloma

February 4th 2025

Pooja Phull, MD, highlights differences between real-world vs clinical trial data for cilta-cel vs ide-cel in relapsed/refractory multiple myeloma.

Dr Winer on Considerations for Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

February 4th 2025

Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

February 4th 2025

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

February 4th 2025

Tom van Meerten, MD, PhD, discusses the role of brexucabtagene autoleucel in high-risk MCL.

Dr Bishop on the Potential Significance of Anito-Cel for the Multiple Myeloma Treatment Paradigm

February 3rd 2025

Michael R. Bishop, MD, discusses the potential significance of anitocabtagene autoleucel for the relapsed/refractory multiple myeloma treatment paradigm.

Dr Landgren on Recent Treatment Paradigm Changes in Multiple Myeloma

February 3rd 2025

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

Dr Bardia on the FDA Approval of Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer

February 3rd 2025

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of Dato-DXd for pretreated, hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Dr Moore on the Relationship Between Biomarker Expression and Efficacy With ADCs in Ovarian Cancer

February 1st 2025

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

Dr Chase on the Importance of QOL and PRO Measures in Gynecologic Oncology

February 1st 2025

Dana M. Chase, MD, discusses the importance of quality of life and patient-reported outcome measures in gynecologic oncology.

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

February 1st 2025

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

February 1st 2025

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Dr Leslie on the Efficacy of Axi-Cel in Relapsed/Refractory MZL

January 31st 2025

Lori A. Leslie, MD, discusses efficacy data from the phase 2 ZUMA-5 trial evaluating axi-cel in relapsed/refractory marginal zone lymphoma.

Dr Raghav on ABBV-400 Plus 5-FU, Folinic Acid, and Bevacizumab in Previously Treated mCRC

January 31st 2025

Kanwal PS Raghav, MBBS, MD, discusses ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated mCRC.

Dr Dotan on the Prognostic Value of QOL Assessments in Older Patients with Pancreatic Cancer

January 31st 2025

Efrat Dotan, MD, discusses gemcitabine plus nab-paclitaxel vs 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with metastatic pancreatic cancer.

Dr Patel on Second Primary Cancer Prevention Strategies After CAR T-Cell Therapy

January 31st 2025

Shyam A. Patel, MD, PhD, discusses secondary prevention strategies that may mitigate the risk of developing SPCs after receipt of CAR T-cell therapy.